Results 21 to 30 of about 606,321 (264)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.

JAMA Netw Open, 2022
ImportanceSome patients treated with nirmatrelvir-ritonavir have experienced rebound of COVID-19 infections and symptoms; however, data are scarce on whether viral rebound also occurs in patients with COVID-19 receiving or not receiving molnupiravir.ObjectiveTo examine the incidence of viral rebound in patients with COVID-19 who were treated with the ...
Wong GL, Yip TC, Lai MS, Wong VW, Hui DS, Lui GC.   +5 more
europepmc   +3 more sources

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption.

PLoS Pathogens, 2021
Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb) administration previously delayed viral rebound and induced SHIV remission.
Denise C Hsu, Alexandra Schuetz, Rawiwan Imerbsin, Decha Silsorn, Amarendra Pegu, Dutsadee Inthawong, Jumpol Sopanaporn, Pornsuk Visudhiphan, Weerawan Chuenarom, Boot Keawboon, Wei Shi, Merlin L Robb, John R Mascola, Romas Geleziunas, Richard A Koup, Dan H Barouch, Nelson L Michael, Sandhya Vasan   +17 more
doaj   +1 more source

Illustration of a Measure to Combine Viral Suppression and Viral Rebound in Studies of HIV Therapy [PDF]

JAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
Viral load is an important tool for assessing antiretroviral treatment efficacy. However, the most common viral load endpoint, virologic failure, may be flawed. We illustrate an alternative endpoint that estimates the average time patients spent suppressed prior to rebound in the AIDS Clinical Trials Group A5095 trial.
Jessie K, Edwards, Stephen R, Cole, Adaora, Adimora, Jason, Fine, Jeff, Martin, Joseph, Eron   +5 more
openaire   +2 more sources

Viral suppression in HIV studies: Combining times to suppression and rebound [PDF]

Biometrics, 2014
SummaryIn HIV‐1 clinical trials the interest is often to compare how well treatments suppress the HIV‐1 RNA viral load. The current practice in statistical analysis of such trials is to define a single ad hoc composite event which combines information about both the viral load suppression and the subsequent viral rebound, and then analyze the data ...
Gouskova, Natalia A., Cole, Stephen R., Eron, Joseph J., Fine, Jason P.   +3 more
openaire   +2 more sources

Viral and Symptom Rebound in Untreated COVID-19 Infection

, 2022
Summary Background There are reports of viral RNA and symptom rebound in people with COVID-19 treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories of COVID-19 has not been well described, we evaluated the incidence of viral and symptom rebound in untreated ...
Deo, Rinki, Choudhary, Manish C., Moser, Carlee, Ritz, Justin, Daar, Eric S., Wohl, David A., Greninger, Alexander L., Eron, Joseph J., Currier, Judith S., Hughes, Michael D., Smith, Davey M., Chew, Kara W., Li, Jonathan Z.   +12 more
openaire   +2 more sources

Timing of initiation of anti-retroviral therapy predicts post-treatment control of SIV replication.

PLoS Pathogens, 2023
One approach to 'functional cure' of HIV infection is to induce durable control of HIV replication after the interruption of antiretroviral therapy (ART).
Mykola Pinkevych, Steffen S Docken, Afam A Okoye, Christine M Fennessey, Gregory Q Del Prete, Maria Pino, Justin L Harper, Michael R Betts, Mirko Paiardini, Brandon F Keele, Miles P Davenport   +10 more
doaj   +1 more source

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART

JCI Insight, 2021
Understanding viral rebound in pediatric HIV-1 infection may inform the development of alternatives to lifelong antiretroviral therapy (ART) to achieve viral remission.
Veronica Obregon-Perko, Katherine M. Bricker, Gloria Mensah, Ferzan Uddin, Laura Rotolo, Daryll Vanover, Yesha Desai, Philip J. Santangelo, Sherrie Jean, Jennifer S. Wood, Fawn C. Connor-Stroud, Stephanie Ehnert, Stella J. Berendam, Shan Liang, Thomas H. Vanderford, Katharine J. Bar, George M. Shaw, Guido Silvestri, Amit Kumar, Genevieve G. Fouda, Sallie R. Permar, Ann Chahroudi   +21 more
doaj   +1 more source

Models of SIV rebound after treatment interruption that involve multiple reactivation events

PLoS Computational Biology, 2020
In order to assess the efficacy of novel HIV-1 treatments leading to a functional cure, the time to viral rebound is frequently used as a surrogate endpoint. The longer the time to viral rebound, the more efficacious the therapy.
Christiaan H. van Dorp, Jessica M. Conway, Dan H. Barouch, James B. Whitney, Alan S. Perelson, Miles P. Davenport   +5 more
doaj   +2 more sources

The rate of viral rebound after attainment of an HIV load < 50 copies/mL according to specific antiretroviral drugs in use: Results from a multicenter cohort study [PDF]

, 2005
Background. Relatively few data are available on the association between the use of specific antiretroviral drugs and the rate of viral rebound in those attaining a viral load (VL) 500 copies/ mL).
Smith, CJ, Smith, C J, Phillips, AN, Porter, K, Scullard, G, Hill, T, Fisher, M, Phillips, A N, Easterbrook, P, Johnson, MA, Gilson, R, Sabin, C A, Gazzard, B, United Kingdom HIV Cohort Study, Matthias, R, Sabin, CA, Johnson, M A   +16 more
core   +1 more source

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound [PDF]

Cell Reports, 2020
Changes in antibody glycosylation are linked to inflammation across several diseases. Alterations in bulk antibody galactosylation can predict rheumatic flares, act as a sensor for immune activation, predict gastric cancer relapse, track with biological age, shift with vaccination, change with HIV reservoir size on therapy, and decrease in HIV and HCV ...
Rasmus Offersen, Wen-Han Yu, Eileen P. Scully, Boris Julg, Zelda Euler, Saheli Sadanand, Dario Garcia-Dominguez, Lu Zheng, Thomas A. Rasmussen, Madeleine F. Jennewein, Caitlyn Linde, Jessica Sassic, Giuseppe Lofano, Selena Vigano, Kathryn E. Stephenson, Stephanie Fischinger, Todd J. Suscovich, Mathias Lichterfeld, Douglas Lauffenburger, Erik S. Rosenberg, Todd Allen, Marcus Altfeld, Richelle C. Charles, Lars Østergaard, Martin Tolstrup, Dan H. Barouch, Ole S. Søgaard, Galit Alter   +27 more
openaire   +5 more sources